美国康涅狄格州纽黑文、中国南京，2019年11月5日 – 先声药业与Aeromics公司今日宣布，双方签署独家合作协议，将在大中华区（包括中国大陆、香港、澳门及台湾地区）共同研发和商业化脑水肿治疗药物AER-271。根据合作条款，先声药业将负责大中华区域内AER-271的临床开发和商业化。AER-271是临床阶段的抗脑水肿药物，开发用来治疗脑卒中和其他适应症。
Aeromics and Simcere Announce Collaboration and License Agreement for AER-271 in Greater China
New Haven, Connecticut, USA, Nanjing, China, 5th November 2019 – Simcere Pharmaceutical Group andAeromics , Inc. Today announce collaboration and exclusive license agreement for AER-271, a clinical-stage anti-edema therapy, being developed for the treatmentof stroke and other indications, in Greater China (mainland China, Hong Kong, Macau and Taiwan). According to the agreement, Simcere will be responsible for the clinical development and commercialization of AER-271 in Greater China.
“We are delighted to be working with Simcere to develop AER-271 in China. Simcere’s leading position in the Greater China stroke market, their strengths in manufacturing and the collaborative nature of their team made for an ideal partner for Aeromics,” said Thomas Zindrick, Aeromics’ Executive Vice Chairman.
Dr. Pin Wang, CSO of Simcere stated on the collaboration, “Edema is a serious complication among many common illnesses of the central nervous system (CNS) such as brain injury and cerebrovascular diseases, with a huge unmet medical need. Aeromics has an excellent research team and expertise in the stroke area, while Simcere has extensive experience in the drug development and commercialization of CNS diseases. We are pleased to have the opportunity to collaborate with Aeromics and hope we will bring AER-271 to patients soon with our joint efforts. ”
Dr. Peter Agre, Aeromics Board member, the 2003 Nobel Prize in Chemistry for discovery of the aquaporin water channels and commented, “By bringing together the complementary expertise of Aeromics and Simcere, I am very gratified we will together advance the development of a therapeutic for a significant unmet medical need, based on the initial insights into aquaporin biology.”
Under terms of the collaboration, Aeromics will receive an up-front payment and additional payments contingent on certain development, regulatory, and commercial milestones, plus tiered royalties on net sales ranging from highsingle digit to double digit percentages. Simcere will be responsible for leading development and commercialization of AER-271 in Greater China and will receive a single-digit percentage royalty from the net sales of AER-271 in therest of the world. Detailed financial terms were not disclosed.
Every 20-30 seconds someone in China suffers from a stroke. Roughly 2,500,000 strokes are seen in China each year, many of which suffer life-threatening and severely disabling cerebral edema, or brain swelling, and may benefit from ananti-edema medication. Aquaporin-4 (AQP4) water channels are the primary routeof water movement into the central nervous system under conditions of ischemia.
AER-271 is a first-in-class, proprietary, intravenous (IV) prodrug thatdelivers AER-270, a potent inhibitor of AQP4 water channels for the treatment cerebral edema (brain swelling) in patients that have suffered ischemic strokes. AER-271 is an investigational drug that has successfully completed a Phase 1 study and is not yet approved by any regulatory agency.
Aeromics is a privately held, clinical-stage pharmaceutical company dedicated to fundamentally changing the way various conditions resulting from the loss of water homeostasis are treated.
For more information about AER-271 and Aeromics, please visit: www.aeromics.com.
Simcere is a research and development-driven Chinese pharmaceutical company with a State Key Lab of Translational Medicine and Innovative Drug Development, committed to delivering high quality and effective therapies to patients. Simcere achieves this by focusing its efforts on therapeutic areas of neurology, oncology, immunology diseases etc. By leverage of its commercial capability, all top products of the company have a leading market share in China. Simcere continues to promote the advance of international scientific and medical breakthroughs through an open and collaborative R&D strategy, and extensive strategic partnerships with several multi-national companies.
For more information, please visit: